CVS Stock Traders on High Alert as Debt Burden Weighs Heavily

CVS Health (CVS) stock has taken a hit in recent months, falling 12.7% without any company-specific news. This decline is not unique to CVS, as its peers UnitedHealth, Cigna, and Elevance Health have also seen their shares fall.

The S&P 500 index rose 0.6% over the same period, highlighting the disparity between CVS's performance and that of the broader market. As a result, CVS stock now trades at 22.5% below its 52-week high.

CVS has experienced significant growth in recent years, with revenue reaching $415.1 billion over the last twelve months, up from $278.3 billion five years ago. However, this expansion has come at a cost, as the company's profit margins remain thin, with CVS keeping only 3.4% of revenue as operating profit.

The company's debt levels are also a concern, amounting to 70% of its market value, compared to just 21% for the S&P 500. This heavy debt burden amplifies the market risk for CVS, making it vulnerable to further declines in the event of a downturn.